Frequency of BRCA1/BRCA2 mutations in a population‐based sample of young breast carcinoma cases

BACKGROUND There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carc...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 88; no. 6; pp. 1393 - 1402
Main Authors Malone, Kathleen E., Daling, Janet R., Neal, Cassandra, Suter, Nicola M., O'Brien, Cecilia, Cushing‐Haugen, Kara, Jonasdottir, Thora J., Thompson, Jennifer D., Ostrander, Elaine A.
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 15.03.2000
Wiley-Liss
Subjects
Online AccessGet full text
ISSN0008-543X
1097-0142
DOI10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P

Cover

Loading…
Abstract BACKGROUND There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carcinoma patients drawn from a population‐based study. In the current study the authors present new findings concerning BRCA2 mutation frequency in this same population, as well as summary data regarding the combined contribution of these two genes. METHODS Subjects were drawn from two population‐based, case‐control studies of breast carcinoma in young women conducted in western Washington State and focused on 1) women diagnosed with breast carcinoma before age 35 years (n = 203); and 2) women with a first‐degree family history of breast carcinoma who were diagnosed before age 45 years (n = 225). Similarities and differences between BRCA2 carriers and BRCA1 carriers were analyzed in terms of age at diagnosis, family history status, and disease features. RESULTS Of cases diagnosed before age 35 years, all of whom were unselected for family history, 9.4% carried germline mutations (3.4% for BRCA2 and 5.9% for BRCA1). Of cases diagnosed before age 45 years who had a first‐degree family history of breast carcinoma, 12.0% carried germline mutations (4.9% for BRCA2 and 7.1% for BRCA1). Increased frequencies of mutations were observed in cases with a personal or family history of early age at diagnosis and in those with four or more family members affected with breast carcinoma. BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma. CONCLUSIONS Overall, given current constraints on health care resources, these data suggest that screening for germline mutations in these breast carcinoma susceptibility genes may have the greatest impact on overall health care if it is prioritized toward high and moderate risk populations. Cancer 2000;88:1393–1402. © 2000 American Cancer Society. The data from the current study show that 9.5% of women diagnosed with breast carcinoma before age 35 years who were unselected for family history and 12.0% of women diagnosed before age 45 years who had a first‐degree family history of breast carcinoma were found to be either BRCA1 or BRCA2 carriers. Analysis of particular subsets of cases highlighted features of family history that may specifically affect risk.
AbstractList BACKGROUND There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carcinoma patients drawn from a population‐based study. In the current study the authors present new findings concerning BRCA2 mutation frequency in this same population, as well as summary data regarding the combined contribution of these two genes. METHODS Subjects were drawn from two population‐based, case‐control studies of breast carcinoma in young women conducted in western Washington State and focused on 1) women diagnosed with breast carcinoma before age 35 years (n = 203); and 2) women with a first‐degree family history of breast carcinoma who were diagnosed before age 45 years (n = 225). Similarities and differences between BRCA2 carriers and BRCA1 carriers were analyzed in terms of age at diagnosis, family history status, and disease features. RESULTS Of cases diagnosed before age 35 years, all of whom were unselected for family history, 9.4% carried germline mutations (3.4% for BRCA2 and 5.9% for BRCA1). Of cases diagnosed before age 45 years who had a first‐degree family history of breast carcinoma, 12.0% carried germline mutations (4.9% for BRCA2 and 7.1% for BRCA1). Increased frequencies of mutations were observed in cases with a personal or family history of early age at diagnosis and in those with four or more family members affected with breast carcinoma. BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma. CONCLUSIONS Overall, given current constraints on health care resources, these data suggest that screening for germline mutations in these breast carcinoma susceptibility genes may have the greatest impact on overall health care if it is prioritized toward high and moderate risk populations. Cancer 2000;88:1393–1402. © 2000 American Cancer Society. The data from the current study show that 9.5% of women diagnosed with breast carcinoma before age 35 years who were unselected for family history and 12.0% of women diagnosed before age 45 years who had a first‐degree family history of breast carcinoma were found to be either BRCA1 or BRCA2 carriers. Analysis of particular subsets of cases highlighted features of family history that may specifically affect risk.
There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carcinoma patients drawn from a population-based study. In the current study the authors present new findings concerning BRCA2 mutation frequency in this same population, as well as summary data regarding the combined contribution of these two genes. Subjects were drawn from two population-based, case-control studies of breast carcinoma in young women conducted in western Washington State and focused on 1) women diagnosed with breast carcinoma before age 35 years (n = 203); and 2) women with a first-degree family history of breast carcinoma who were diagnosed before age 45 years (n = 225). Similarities and differences between BRCA2 carriers and BRCA1 carriers were analyzed in terms of age at diagnosis, family history status, and disease features. Of cases diagnosed before age 35 years, all of whom were unselected for family history, 9.4% carried germline mutations (3.4% for BRCA2 and 5.9% for BRCA1). Of cases diagnosed before age 45 years who had a first-degree family history of breast carcinoma, 12.0% carried germline mutations (4.9% for BRCA2 and 7.1% for BRCA1). Increased frequencies of mutations were observed in cases with a personal or family history of early age at diagnosis and in those with four or more family members affected with breast carcinoma. BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma. Overall, given current constraints on health care resources, these data suggest that screening for germline mutations in these breast carcinoma susceptibility genes may have the greatest impact on overall health care if it is prioritized toward high and moderate risk populations.
There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carcinoma patients drawn from a population-based study. In the current study the authors present new findings concerning BRCA2 mutation frequency in this same population, as well as summary data regarding the combined contribution of these two genes. Subjects were drawn from two population-based, case-control studies of breast carcinoma in young women conducted in western Washington State and focused on 1) women diagnosed with breast carcinoma before age 35 years (n = 203); and 2) women with a first-degree family history of breast carcinoma who were diagnosed before age 45 years (n = 225). Similarities and differences between BRCA2 carriers and BRCA1 carriers were analyzed in terms of age at diagnosis, family history status, and disease features. Of cases diagnosed before age 35 years, all of whom were unselected for family history, 9.4% carried germline mutations (3.4% for BRCA2 and 5.9% for BRCA1). Of cases diagnosed before age 45 years who had a first-degree family history of breast carcinoma, 12.0% carried germline mutations (4.9% for BRCA2 and 7.1% for BRCA1). Increased frequencies of mutations were observed in cases with a personal or family history of early age at diagnosis and in those with four or more family members affected with breast carcinoma. BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma. Overall, given current constraints on health care resources, these data suggest that screening for germline mutations in these breast carcinoma susceptibility genes may have the greatest impact on overall health care if it is prioritized toward high and moderate risk populations.
There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carcinoma patients drawn from a population-based study. In the current study the authors present new findings concerning BRCA2 mutation frequency in this same population, as well as summary data regarding the combined contribution of these two genes.BACKGROUNDThere is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the basis of extreme family history profiles. Toward this end, the authors previously reported results with regard to BRCA1 in breast carcinoma patients drawn from a population-based study. In the current study the authors present new findings concerning BRCA2 mutation frequency in this same population, as well as summary data regarding the combined contribution of these two genes.Subjects were drawn from two population-based, case-control studies of breast carcinoma in young women conducted in western Washington State and focused on 1) women diagnosed with breast carcinoma before age 35 years (n = 203); and 2) women with a first-degree family history of breast carcinoma who were diagnosed before age 45 years (n = 225). Similarities and differences between BRCA2 carriers and BRCA1 carriers were analyzed in terms of age at diagnosis, family history status, and disease features.METHODSSubjects were drawn from two population-based, case-control studies of breast carcinoma in young women conducted in western Washington State and focused on 1) women diagnosed with breast carcinoma before age 35 years (n = 203); and 2) women with a first-degree family history of breast carcinoma who were diagnosed before age 45 years (n = 225). Similarities and differences between BRCA2 carriers and BRCA1 carriers were analyzed in terms of age at diagnosis, family history status, and disease features.Of cases diagnosed before age 35 years, all of whom were unselected for family history, 9.4% carried germline mutations (3.4% for BRCA2 and 5.9% for BRCA1). Of cases diagnosed before age 45 years who had a first-degree family history of breast carcinoma, 12.0% carried germline mutations (4.9% for BRCA2 and 7.1% for BRCA1). Increased frequencies of mutations were observed in cases with a personal or family history of early age at diagnosis and in those with four or more family members affected with breast carcinoma. BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma.RESULTSOf cases diagnosed before age 35 years, all of whom were unselected for family history, 9.4% carried germline mutations (3.4% for BRCA2 and 5.9% for BRCA1). Of cases diagnosed before age 45 years who had a first-degree family history of breast carcinoma, 12.0% carried germline mutations (4.9% for BRCA2 and 7.1% for BRCA1). Increased frequencies of mutations were observed in cases with a personal or family history of early age at diagnosis and in those with four or more family members affected with breast carcinoma. BRCA2 mutations were less common than BRCA1 mutations in families with any history of ovarian carcinoma.Overall, given current constraints on health care resources, these data suggest that screening for germline mutations in these breast carcinoma susceptibility genes may have the greatest impact on overall health care if it is prioritized toward high and moderate risk populations.CONCLUSIONSOverall, given current constraints on health care resources, these data suggest that screening for germline mutations in these breast carcinoma susceptibility genes may have the greatest impact on overall health care if it is prioritized toward high and moderate risk populations.
Author Suter, Nicola M.
Thompson, Jennifer D.
Malone, Kathleen E.
Cushing‐Haugen, Kara
Daling, Janet R.
O'Brien, Cecilia
Ostrander, Elaine A.
Neal, Cassandra
Jonasdottir, Thora J.
Author_xml – sequence: 1
  givenname: Kathleen E.
  surname: Malone
  fullname: Malone, Kathleen E.
– sequence: 2
  givenname: Janet R.
  surname: Daling
  fullname: Daling, Janet R.
– sequence: 3
  givenname: Cassandra
  surname: Neal
  fullname: Neal, Cassandra
– sequence: 4
  givenname: Nicola M.
  surname: Suter
  fullname: Suter, Nicola M.
– sequence: 5
  givenname: Cecilia
  surname: O'Brien
  fullname: O'Brien, Cecilia
– sequence: 6
  givenname: Kara
  surname: Cushing‐Haugen
  fullname: Cushing‐Haugen, Kara
– sequence: 7
  givenname: Thora J.
  surname: Jonasdottir
  fullname: Jonasdottir, Thora J.
– sequence: 8
  givenname: Jennifer D.
  surname: Thompson
  fullname: Thompson, Jennifer D.
– sequence: 9
  givenname: Elaine A.
  surname: Ostrander
  fullname: Ostrander, Elaine A.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1316264$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10717622$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1u1DAQxy1URLeFV0A5INQesvVHYjtbhLSktKxUsVUBCYnDaJJMUFC-iDdCe-MR-ow8CU53C9zwwR6Pfv-R7N8RO2i7lhhbCj4XnMuzkw-rdHUqeGJCLiJ5IrlfSsSn1i70K6EStVgsVxdh-j69Fea1mvN5uj6X4c0jNvuTOmAzn7JhHKnPh-zIuW_-amSsnrBDwY0wWsoZw8uBvo_U5tugK4M3t-lSnE27DJpxg5uqa11QtQEGfdeP9X3j18-7DB0VgcOmr2nKbbux_RpkA6HbBDkOedV2DfrKkXvKHpdYO3q2P4_Zp8u3H9N34fX6apUur8NexcKEWmBJmYyMJpXnklBbRTwqNQklsYgLG_meMpnlgssyErGloiDSBSEWWaaO2cvd3H7o_IvcBprK5VTX2FI3OjA80VEi5H9BYWIdxzLx4PM9OGYNFdAPVYPDFh5-zwMv9gC6HOtywDav3F9OCS115LEvO-xHVdP2nzEw2YZJNkzaYNIGD7LBWtAwyQbvGnauQQGHdA0SbvYd9RvfkaSE
CODEN CANCAR
ContentType Journal Article
Copyright Copyright © 2000 American Cancer Society
2000 INIST-CNRS
Copyright 2000 American Cancer Society.
Copyright_xml – notice: Copyright © 2000 American Cancer Society
– notice: 2000 INIST-CNRS
– notice: Copyright 2000 American Cancer Society.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TO
H94
7X8
DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitleList
Oncogenes and Growth Factors Abstracts
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0142
EndPage 1402
ExternalDocumentID 10717622
1316264
CNCR17
Genre article
Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: National Cancer Institute
  funderid: R01‐CA‐63705; R01‐CA‐41416; N01‐CP‐95671; R01‐CA‐59736; R21‐CA‐66186
– fundername: NCI NIH HHS
  grantid: R01-CA-63705
– fundername: NCI NIH HHS
  grantid: N01-CP-95671
– fundername: NCI NIH HHS
  grantid: R01-CA-41416
GroupedDBID ---
-~X
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1L6
1OC
24P
29B
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AARRQ
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABHFT
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AGNAY
AHBTC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
F00
F01
F04
F5P
FD6
FUBAC
G-S
G.N
GNP
GODZA
GX1
H.X
HBH
HGLYW
HHY
HHZ
HZ~
H~9
IH2
IX1
J0M
J5H
JPC
KBYEO
KQQ
KZ1
L7B
LATKE
LAW
LC2
LC3
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NEJ
NF~
NNB
O66
O9-
OHT
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
SJN
SUPJJ
TEORI
UDS
UHB
V2E
V8K
V9Y
VH1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XPP
XV2
Y6R
Z0Y
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAQOH
AEFGJ
AEYWJ
AGHNM
AGXDD
AGYGG
AIDQK
AIDYY
C1A
EMOBN
EX3
HF~
IQODW
LMP
RSU
RYL
WHG
YQJ
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
7TO
H94
7X8
ID FETCH-LOGICAL-p3517-61afeb2476e3cc2ea683e04f6e132ad5d84ea637b80102f4158eddee6deaadbb3
IEDL.DBID DR2
ISSN 0008-543X
IngestDate Fri Jul 11 05:50:48 EDT 2025
Fri Jul 11 03:19:46 EDT 2025
Wed Feb 19 02:36:09 EST 2025
Mon Jul 21 09:14:07 EDT 2025
Wed Jan 22 16:31:35 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Human
Mammary gland diseases
Carcinoma
Premenopause
Germ line
Young adult
Genetics
Frequency
Malignant tumor
Mammary gland
Mutation
Tumor suppressor gene
Language English
License CC BY 4.0
Copyright 2000 American Cancer Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p3517-61afeb2476e3cc2ea683e04f6e132ad5d84ea637b80102f4158eddee6deaadbb3
Notes This article repesents a multidisciplinary effort. Dr. Ostrander led the molecular analysis and Dr. Malone led the epidemiologic and statistical component. Both authors contributed equally to this work.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 10717622
PQID 17565529
PQPubID 23462
PageCount 10
ParticipantIDs proquest_miscellaneous_70964912
proquest_miscellaneous_17565529
pubmed_primary_10717622
pascalfrancis_primary_1316264
wiley_primary_10_1002_SICI_1097_0142_20000315_88_6_1393_AID_CNCR17_3_0_CO_2_P_CNCR17
PublicationCentury 2000
PublicationDate 15 March 2000
PublicationDateYYYYMMDD 2000-03-15
PublicationDate_xml – month: 03
  year: 2000
  text: 15 March 2000
  day: 15
PublicationDecade 2000
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: New York, NY
– name: United States
PublicationTitle Cancer
PublicationTitleAlternate Cancer
PublicationYear 2000
Publisher John Wiley & Sons, Inc
Wiley-Liss
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley-Liss
References 1997; 278
1997; 336
1997; 60
1995; 57
1995; 56
1995; 11
1998; 279
1991; 338
1996; 58
1996; 14
1998; 352
1998; 62
1996; 12
1994; 86
1998; 16
1994; 8
1994; 265
1991; 48
1993; 16
1997; 10
1997; 14
1995; 87
1996; 334
1990; 250
1996; 336
References_xml – volume: 58
  start-page: 271
  year: 1996
  end-page: 80
  article-title: Haplotype and phenotype analysis of six recurrent mutations in 61 families: results of an international study
  publication-title: Am J Hum Genet
– volume: 62
  start-page: 676
  year: 1998
  end-page: 89
  article-title: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
  publication-title: Am J Hum Genet
– volume: 250
  start-page: 1684
  year: 1990
  end-page: 9
  article-title: Linkage of early‐onset familial breast cancer to chromosome 17q21
  publication-title: Science
– volume: 56
  start-page: 265
  year: 1995
  end-page: 71
  article-title: Breast and ovarian cancer incidence in ‐mutation carriers. Breast Cancer Linkage Consortium
  publication-title: Am J Hum Genet
– volume: 16
  start-page: 325
  year: 1993
  end-page: 32
  article-title: The sensitivity of single‐strand conformation polymorphism analysis for the detection of single base substitutions
  publication-title: Genomics
– volume: 279
  start-page: 915
  year: 1998
  end-page: 21
  article-title: Frequency of breast cancer attributable to in a population‐based series of American women
  publication-title: JAMA
– volume: 60
  start-page: 1031
  year: 1997
  end-page: 40
  article-title: in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to or
  publication-title: Am J Hum Genet
– volume: 60
  start-page: 313
  year: 1997
  end-page: 9
  article-title: Mutation analysis of and in a male breast cancer population
  publication-title: Am J Hum Genet
– volume: 60
  start-page: 496
  year: 1997
  end-page: 504
  article-title: Prevalence and contribution of mutations in breast cancer and ovarian cancer: results from three U.S. population‐based case‐control studies of ovarian cancer
  publication-title: Am J Hum Genet
– volume: 14
  start-page: 2189
  year: 1997
  end-page: 93
  article-title: Infrequency of alterations in head and neck squamous cell carcinoma
  publication-title: Oncogene
– volume: 334
  start-page: 137
  year: 1996
  end-page: 42
  article-title: mutations in a population‐based sample of young women with breast cancer
  publication-title: N Engl J Med
– volume: 12
  start-page: 333
  year: 1996
  end-page: 7
  article-title: The complete gene and mutations in chromosome 13q‐linked kindreds
  publication-title: Nat Genet
– volume: 338
  start-page: 82
  year: 1991
  end-page: 3
  article-title: Familial breast‐ovarian cancer locus on chromosome 17q12‐q23
  publication-title: Lancet
– volume: 279
  start-page: 922
  year: 1998
  end-page: 9
  article-title: mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first‐degree family history
  publication-title: JAMA
– volume: 278
  start-page: 1242
  year: 1997
  end-page: 50
  article-title: sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing
  publication-title: JAMA
– volume: 87
  start-page: 827
  year: 1995
  end-page: 35
  article-title: Oral contraceptives and breast cancer risk among younger women
  publication-title: J Natl Cancer Inst
– volume: 336
  start-page: 1401
  year: 1997
  end-page: 8
  article-title: The risk of cancer associated with specific mutations of and among Ashkenazi Jews
  publication-title: N Engl J Med
– volume: 14
  start-page: 188
  year: 1996
  end-page: 90
  article-title: The carrier frequency of the 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
  publication-title: Nat Genet
– volume: 48
  start-page: 232
  year: 1991
  end-page: 42
  article-title: Genetic analysis of breast cancer in the cancer and steroid hormone study
  publication-title: Am J Hum Genet
– volume: 11
  start-page: 198
  year: 1995
  end-page: 200
  article-title: The carrier frequency of the 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
  publication-title: Nat Genet
– volume: 57
  start-page: 1457
  year: 1995
  end-page: 62
  article-title: Estimates of the gene frequency of and its contribution to breast and ovarian cancer incidence
  publication-title: Am J Hum Genet
– volume: 10
  start-page: 65
  year: 1997
  end-page: 70
  article-title: SSCP analysis: a blind sensitivity trial
  publication-title: Human Mutat
– volume: 336
  start-page: 1409
  year: 1996
  end-page: 15
  article-title: mutations in women attending clinics that evaluate the risk of breast cancer
  publication-title: N Engl J Med
– volume: 60
  start-page: 486
  year: 1997
  end-page: 95
  article-title: Mutations in and in breast cancer families: are there more breast cancer‐susceptibility genes?
  publication-title: Am J Hum Genet
– volume: 336
  start-page: 1416
  year: 1997
  end-page: 21
  article-title: Differential contributions of and to early‐onset breast cancer
  publication-title: N Engl J Med
– volume: 352
  start-page: 1337
  year: 1998
  end-page: 9
  article-title: Population‐based study of risk of breast cancer in carriers of BRCA2 mutation
  publication-title: Lancet
– volume: 14
  start-page: 253
  year: 1996
  end-page: 4
  article-title: A polymorphic stop codon in
  publication-title: Nat Genet
– volume: 8
  start-page: 399
  year: 1994
  end-page: 404
  article-title: Confirmation of by analysis of germline mutations linked to breast and ovarian cancer in ten families
  publication-title: Nat Genet
– volume: 86
  start-page: 1584
  year: 1994
  end-page: 92
  article-title: Risk of breast cancer among young women: relationship to induced abortion
  publication-title: J Natl Cancer Inst
– volume: 16
  start-page: 1713
  year: 1998
  end-page: 21
  article-title: physically associates with p53 and stimulates its transcriptional activity
  publication-title: Oncogene
– volume: 56
  start-page: 254
  year: 1995
  end-page: 64
  article-title: An evaluation of genetic heterogeneity in 145 breast‐ovarian cancer families
  publication-title: Am J Hum Genet
– volume: 60
  start-page: 1013
  year: 1997
  end-page: 20
  article-title: Population genetics of and
  publication-title: Am J Hum Genet
– volume: 8
  start-page: 387
  year: 1994
  end-page: 91
  article-title: Mutations in the gene in families with early‐onset breast and ovarian cancer
  publication-title: Nat Genet
– volume: 57
  start-page: 1284
  year: 1995
  end-page: 97
  article-title: Novel inherited mutations and variable expressivity of alleles, including the founder mutation 185delAG in Ashkenazi Jewish families
  publication-title: Am J Hum Genet
– volume: 265
  start-page: 2088
  year: 1994
  end-page: 90
  article-title: Localization of a breast cancer susceptibility gene, , to chromosome 13q12‐13
  publication-title: Science
SSID ssj0007253
Score 2.0838733
Snippet BACKGROUND There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained...
There is a clear and growing need for data regarding BRCA1 and BRCA2 mutation frequencies among breast carcinoma cases not specifically ascertained on the...
SourceID proquest
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1393
SubjectTerms Adult
Age Factors
Biological and medical sciences
BRCA1
BRCA2
BRCA2 Protein
Breast
breast carcinoma
Breast Neoplasms - genetics
Carcinoma - genetics
Case-Control Studies
Codon - genetics
Confidence Intervals
Female
Frameshift Mutation - genetics
Genes, BRCA1 - genetics
Genetic Markers - genetics
Genetic Predisposition to Disease
Germ-Line Mutation - genetics
Gynecology. Andrology. Obstetrics
Heterozygote
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Mutation, Missense - genetics
Neoplasm Proteins - genetics
Ovarian Neoplasms - genetics
Polymorphism, Genetic - genetics
population
Population Surveillance
Risk Factors
Transcription Factors - genetics
Tumors
Title Frequency of BRCA1/BRCA2 mutations in a population‐based sample of young breast carcinoma cases
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2F%28SICI%291097-0142%2820000315%2988%3A6%3C1393%3A%3AAID-CNCR17%3E3.0.CO%3B2-P
https://www.ncbi.nlm.nih.gov/pubmed/10717622
https://www.proquest.com/docview/17565529
https://www.proquest.com/docview/70964912
Volume 88
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV3dbtMwFLamXUzc8P9TYOALKm0XaRPbcZyCkLqwakXaj8om9c6yE0dCaGm1tBfjBh6BR-DZeBLOqZOWIbhESFGUOImP5C-2v5Mcf4eQV3nIbaHCMshdmQQizU1gEgWnwsHkZ0OTrtatHZ_IowvxfhpPt8iXdi2M14dYf3DDnrEar7GDG1v3N6KhQMA-jLMxOMz4ExVcYgGlCleeYOICKFYKQJZdngHJ4XAI23D8LshOskmUdPkh74W97LTLD1hwBmM4xnshqZps5KcS1qhYhiqIBZ_ukGFjv7-HtvfXlvdau_tKDeQbtDgYbKy99bZegyUMvjQ1tH_pE2f8idneJMqrmW50h3xv28gHuHzqLRe2l3_-TT7yPzbiXXK7YdF06F_7e2TLVffJznETJ_CAmNGVDxG_prOSHkyyYdTHPaOXSx97UNOPFTV0vs5f9uPrN5zRC1obFEzG565xJKQWw_YXNMekS9Xs0sBR7eqH5GJ0eJ4dBU0yiWDO4wiXQprSWSYS6XieM2ek4i4UpXTgj5siLpSAMp5YhSp7JfAa5WDod7JwxhTW8kdku5pV7gmhEfhgZWpEDtO_4EIaaUWqZJxHSWlTJjtk9wbEeu6FQ3TEI_AfRYe8bCHX0JnxD42p3GxZa-ByMo5Z-vc7EnA5RRqxDnns35VN5eiZSwZXzleI_3IBhamZRqCbgAOAWbcga6W01AivBmS1R1ZzHersVDN91pQ8_TfVPiO3vLgBD6L4OdleXC3dLtC8hX2x6os_AUoWMqY
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV3dbtMwFLbGkAY3_P8UGPMFlbaLtEnsOE5BSF1Y1cLaTV0n9c6yE0dCaGm1tBfjao_AK_BqPAnnJGnLEFwipChKnMQnyhfb30mOv0PIm8RlJpVu5iQ2Cx0eJdrRoYRdbmHwM66Oynlrw5Hon_OP02C6Ra5Xc2EqfYj1BzdsGWV_jQ0cP0i3N6qhwMDOBvEAPGb8iwo-MYdSiVNPMHMBFEsJKIsmi4HlMNiEpTv44MSjeOyFTXbEWm4rPmmyQ985vUVuY1bw0ikbbwSoQr_WsXSlE3A23SHd-gba-2j8YG16f2X4QMqOeIcmO52NufeVsbdgCsMvdQEIZFXqjD9x25tUuRzrevfJ99VTqkJcvrSWC9NKvv4mIPk_H-MDcq8m0rRbvfkPyZbNH5GdYR0q8Jjo3mUVJX5FZxk9HMddr41rn14sq_CDgn7OqabzdQqzH9ffcFBPaaFRMxmvu8LOkBqM3F_QBPMu5bMLDVuFLZ6Q897RJO47dT4JZ84CD2dD6swan4fCsiTxrRaSWZdnwoJLrtMglRzKWGgkCu1lQG2khd7fitRqnRrDnpLtfJbb54R64IZlkeYJMADOuNDC8EiKIPHCzES-aJDdGxireaUdojzmgQvJG2RvhbmC9ow_aXRuZ8tCAZ0TQeBHfz8jBK-TR57fIM-ql2VTOTrnwocjkxLyXw6gNrWvEOg65gBgViuQlZRKKIRXAbKqQlYx5ar4RPnqtC558W-q3SN3-pPhsToejD69JHcrrQPmeMErsr24XNpdYH0L87psmD8Blko2wQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV3dbtMwFLbGkCpu-P8pMJYLKm0XaRPbcZyCkLp01Qqsq8Ym9c6yE0dCaGm1tBfjBh6BR-DZeBLOqdOWIbhESFGUOIlP5C_HPic-_g4hL7OAmVwGhZ_ZIvZ5kmlfxxJOuYXBzwQ6Wa5bOx6Jo3P-dhJNtsiX1VoYxw-x_uGGmrHsr1HBZ3nR2ZCGggH2YZgOwWHGSVRwiTmUSlx5gokLoFhKAFm0WApGDoND2HrDvp-O0tMwbrFD1g7a6UmLHVB_fIPc5CKQqBb90w3_VExrGstA-hFnkwbp1S_Q2UPh-2vReyvB-1J2xWsU2e1uxL1xwl6BKIy-1BUAULjMGX8yba9bysuhbnCHfF81kotw-dRezE07-_wbf-R_bMW75HZtRns9993fI1u2vE8ax3WgwAOiB5cuRvzKmxbewWnaCzu4p97FwgUfVN7H0tPebJ3A7MfXbzik516lkTEZn7vCrtAzGLc_9zLMulROLzQcVbZ6SM4Hh2fpkV9nk_BnLApxLaQurKE8FpZlGbVaSGYDXggLDrnOo1xyKGOxkUizV4BhIy30_VbkVuvcGPaIbJfT0j4hXghOWJFonsH4zxkXWhieSBFlYVyYhIom2bkGsZo55hAVshAcSN4kuyvIFWgzTtHo0k4XlQJjTkQRTf5-Rww-J09C2iSP3beyqRxdc0HhytkS8V8uIDM1VQh0HXEAMKsVyEpKJRTCqwBZ5ZBVTAUqPVFUjeuSp_-m2l3SGPcH6v1w9O4ZueWIDpgfRs_J9vxyYXfA5JubF0u1_Am4XzV5
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Frequency+of+BRCA1%2FBRCA2+mutations+in+a+population-based+sample+of+young+breast+carcinoma+cases&rft.jtitle=Cancer&rft.au=Malone%2C+KE&rft.au=Daling%2C+J+R&rft.au=Neal%2C+C&rft.au=Suter%2C+N+M&rft.date=2000-03-15&rft.issn=0008-543X&rft.volume=88&rft.issue=6&rft.spage=1393&rft.epage=1402&rft_id=info:doi/10.1002%2F%28SICI%291097-0142%2820000315%2988%3A6%3C1393%3A%3AAID-CNCR17%3E3.0.CO%3B2-P&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon